GlassScriptPhysician profile
Pompeyo C Chavez
NPI 1821292426
$11,208.39
in general payments reported to CMS, 2019-2025
48 companies · $1,808 in 2025
The $1,808 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,151 · 2020: $760 · 2021: $1,134 · 2022: $1,804 · 2023: $1,832 · 2024: $1,720 · 2025: $1,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,317 · Education: $42.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,317.00 |
| Education | $42.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,078.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,034.67 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $878.25 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Merz North America, INC. | $685.42 | 2020-2022 | |
| Amgen INC. | $683.44 | 2019-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $675.43 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $586.76 | 2022-2025 | Proclaim, Freestyle Libre 3 |
| Corcept Therapeutics | $534.61 | 2024-2025 | Korlym |
| Shockwave Medical, INC | $517.02 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $447.12 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $418.49 | 2020-2025 | |
| Pfizer INC. | $414.90 | 2019-2024 | |
| Amarin Pharma, INC. | $333.78 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $246.78 | 2019-2022 | |
| Abiomed | $229.42 | 2020-2024 | Impella |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pompeyo Chavez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.